Notice of Results
Updated : 15:15
23 May 2018
Consort Medical plc
Notice of Results
Consort Medical plc (LSE: CSRT) ("Consort", "Consort Medical" or the "Group"), a leading one-stop developer and manufacturer of drugs and premium drug delivery devices, will announce its financial results for the year ended 30 April 2018 on Thursday, 14 June 2018.
Enquiries:
Consort Medical | Tel: +44 (0) 1442 867920 |
Jonathan Glenn - Chief Executive Officer | |
Paul Hayes - Chief Financial Officer | |
Investec Bank plc | Tel: +44 (0) 20 7597 5970 |
Gary Clarence | |
Carlton Nelson | |
RBC Capital Markets | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson | |
Laura White | |
FTI Consulting | Tel: +44 (0) 20 3727 1000 |
Ben Atwell / Simon Conway |
About Consort Medical
Consort Medical plc is a leading one-stop developer and manufacturer of drugs and premium drug delivery devices. We partner with pharmaceutical businesses in providing innovative life improving treatments to patients across the world through two integrated activities:
The design, development and manufacture of high performance medical devices for inhaled, injectable, nasal and ocular drug delivery, as well as point of care diagnostics products.
The development, formulation and manufacture of active pharmaceutical ingredients (APIs) and finished dose drugs to the highest quality standards.
We employ over 2,000 people globally and are committed to investing in patient, clinician and customer driven innovation to create new treatments.
Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT) and is organised in two divisions: Bespak and Aesica. www.consortmedical.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.